<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months</h1>
<div class="graphic"><div class="figure"><div class="ttl">Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">In the international series of 816 patients from seven centers, staging cardiac biomarkers were available for 53 percent (432/816). Of these, 24 percent were stage 1 (both NT-proBNP p ≤332 ng/L and cardiac troponin T (cTnT) p ≤0.035 ng/mL or cTnI p ≤0.1 ng/mL), 52 percent stage 2 (NT-proBNP &gt;332 ng/L or cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL), and 24 percent stage 3 (both NT-proBNP &gt;332 ng/L and cTnT &gt;0.035 ng/mL or cTnI &gt;0.1 ng/mL). In these survival curves, results for 377 patients with baseline NT-proBNP greater than or equal to 650 ng/L are shown according to NT-proBNP response or progression at six months.<sup>[1]</sup></div><div class="graphic_reference">References:<br/><ol>
<li>Palladini G, Dispenzieri A, Gertz MA, et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116:1364a.</li></ol>Reprinted by permission from Macmillan Publishers Ltd: Leukemia, Comenzo RL, Reece D, Palladini G, Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, advance online publication, 15 May 2012 (DOI: 10.1038/leu.2012.100). Copyright © 2012. <a href="http://www.nature.com/leu/index.html" style="FONT-STYLE: italic" target="_blank">http://www.nature.com/leu/index.html</a>.</div><div id="graphicVersion">Graphic 86505 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
